0001104659-18-049576.txt : 20180803 0001104659-18-049576.hdr.sgml : 20180803 20180803193152 ACCESSION NUMBER: 0001104659-18-049576 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180802 FILED AS OF DATE: 20180803 DATE AS OF CHANGE: 20180803 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gelone Steven P. CENTRAL INDEX KEY: 0001693064 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37558 FILM NUMBER: 18993229 MAIL ADDRESS: STREET 1: 1000 CONTINENTAL DRIVE STREET 2: SUITE 600 CITY: KING OF PRUSSIA STATE: PA ZIP: 19406 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nabriva Therapeutics plc CENTRAL INDEX KEY: 0001641640 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 56 FITZWILLIAM SQUARE CITY: DUBLIN STATE: L2 ZIP: 2 BUSINESS PHONE: (610) 816-6640 MAIL ADDRESS: STREET 1: 1000 CONTINENTAL DRIVE STREET 2: SUITE 600 CITY: KING OF PRUSSIA STATE: PA ZIP: 19406 FORMER COMPANY: FORMER CONFORMED NAME: Nabriva Therapeutics AG DATE OF NAME CHANGE: 20150507 4 1 a4.xml 4 X0306 4 2018-08-02 0 0001641640 Nabriva Therapeutics plc NBRV 0001693064 Gelone Steven P. 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406 0 1 0 0 President and COO Stock Option 2018-08-02 4 A 0 7500 0.00 A 2028-08-02 Ordinary Shares 7500 7500 D Restricted Stock Units 2018-08-02 4 A 0 32000 0.00 A 2020-01-31 Ordinary Shares 32000 32000 D The exercise price is $2.49 per share. The option award was granted on August 2, 2018. Vesting began on July 24, 2018 and ends on July 24, 2022. Twenty-five percent (25%) of the option award will vest on July 24, 2019, and the remaining seventy-five percent (75%) of the option award will vest on a monthly pro-rata basis over the remaining vesting period. The restricted stock units shall convert into ordinary shares on a one-for-one basis upon vesting of the units. The restricted share units were granted on August 2, 2018, and are subject to vesting as follows: 50% will vest upon certification by the board of directors of the receipt of approval by the United States Food and Drug Administration (the "FDA") of a new drug application for lefamulin, and 50% will vest on the first anniversary of such certification by the board of directors, provided, in each case, that the registrant is performing services to Nabriva Therapeutics plc on the applicable vesting dates. If the FDA does not approve a new drug application for lefamulin by January 31, 2020, the restricted share units will terminate in full. /s/ Gary L. Sender, by power-of-attorney 2018-08-03